The biotech will supply Canada with fewer doses of its coronavirus vaccine while reaching a financial agreement for the forfeiting of certain doses previously scheduled for delivery.
At the World Vaccine Congress in Washington, D.C. on Wednesday, Maryland-based Novavax presented data on its COVID-19 booster and COVID-influenza combination vaccine candidate. Novavax shares rose 12 percent Thursday following the presentation.
On February 28, Novavax issued a candid warning to investors: it may not be able to continue operations beyond February 2024.
France’s Haute Autorite de Sante public health body advised the government not to use Valneva’s VLA2001 COVID-19 vaccine as part of its wider vaccination strategy, although two rival products should be included as booster shots.
With recent years of acquisitions and divestitures in the rearview, Takeda can focus on what matters most: growing its brands.
The European Medicines Agency (EMA) is recommending Novavax’s COVID-19 vaccine carry a warning of the possibility of two types of heart inflammation, an added burden for a shot that has so far failed to win wide uptake.
The European Medicines Agency on Thursday identified severe allergic reactions as potential side effects of Novavax Inc.’s COVID-19 vaccine.